91 related articles for article (PubMed ID: 27353471)
1. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Yamasaki H; Miyamoto M; Yamamoto Y; Kondo T; Watanabe T; Ohta T
Genes Cells; 2016 Aug; 21(8):852-60. PubMed ID: 27353471
[TBL] [Abstract][Full Text] [Related]
2. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
4. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
[TBL] [Abstract][Full Text] [Related]
5. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
[TBL] [Abstract][Full Text] [Related]
7. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
Zhan L; Qin Q; Lu J; Liu J; Zhu H; Yang X; Zhang C; Xu L; Liu Z; Cai J; Ma J; Dai S; Tao G; Cheng H; Sun X
Dis Esophagus; 2016 Apr; 29(3):215-23. PubMed ID: 25604309
[TBL] [Abstract][Full Text] [Related]
8. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
[TBL] [Abstract][Full Text] [Related]
10. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Saleh EM
Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
14. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
15. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
[TBL] [Abstract][Full Text] [Related]
17. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
19. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
